1. "2011"
Formats
  1. Journal Article (2141)
  2. Meeting Abstract (988)
  3. Book Section (224)
  4. Conference Paper (18)
  5. Book Whole (11)
Groups
  1. Department of Medicine (1176)
  2. Surgery (803)
  3. GSK Faculty (796)
  4. Solid Tumor Oncology Division (659)
  5. Sloan Kettering Institute Faculty (606)
  6. Survivorship Research (542)

More Groups

People
  1. Robert Soslow (64)
  2. Clifford Hudis (60)
  3. Mithat Gonen (54)
  4. Marc Ladanyi (52)
  5. Robert Motzer (52)
  6. Valerie Rusch (47)

More People

Years
  1. 2011 (3382)
Publications
  1. Journal of Clinical Oncology (319)
  2. Blood (147)
  3. Cancer Research (122)
  4. International Journal of Radiation Oncology, Biology, Physics (104)
  5. Modern Pathology (70)
  6. Laboratory Investigation (65)

More Publications

Publishers
  1. Elsevier Inc. (450)
  2. American Society of Clinical Oncology (327)
  3. Springer (231)
  4. American Association for Cancer Research (180)
  5. Nature Publishing Group (157)
  6. Wiley Blackwell (154)

More Publishers

Results (3382)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathogeneses of noninflammatory locally advanced breast cancer
    Meeting Abstract

    Dahi, P. B.; Axiotis, C. A.; Dhiran, K.; Weedon, J.; El-Tamer, M.; Braverman, A. S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Dang, C. T.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations
    Meeting Abstract

    D'Angelo, S. P.; Park, B. J.; Krug, L. M.; Crevar, C.; Medina, C. E.; Sumner, D. K.; Richman, J.; Coeshott, C.; Apelian, D.; Cohn, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Meeting Abstract

    Crinò, L.; Kim, D.; Riely, G. J.; Janne, P. A.; Blackhall, F. H.; Camidge, D. R.; Hirsh, V.; Mok, T.; Solomon, B. J.; Park, K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival
    Meeting Abstract

    Cioffi, A.; Italiano, A.; Penel, N.; Berge, Y.; Toulmonde, M.; Salas, S.; Chevreau, C.; Le Cesne, A.; Duffaud, F.; D'Adamo, D. R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST)
    Meeting Abstract

    D'Adamo, D. R.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C.; Qin, L.; Antonescu, C.; Lefkowitz, R. A.; Schwartz, G. K.; Maki, R. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • FDG-PET in the staging and prognosis of T-cell lymphoma
    Meeting Abstract

    Casulo, C.; Maragulia, J.; Zelenetz, A. D.; Schöder, H.; Feeney, J.; Horwitz, S. M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Gemcitabine (gem) as salvage therapy in metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Cercek, A.; Gollub, M.; Saltz, L.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance
    Meeting Abstract

    Chaft, J. E.; Oxnard, G. R.; Miller, V. A.; Kris, M. G.; Sima, C. S.; Riely, G. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Cella, D.; Escudier, B.; Rini, B. I.; Chen, C.; Bhattacharyya, H.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save